Innovative Aqueous Nanoemulsion Prepared by Phase Inversion Emulsification with Exceptional Homogeneity.
homogenous
intranasal
low energy
nanoemulsion
phase inversion
propylene glycol monocaprylate type II
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
04 Jul 2023
04 Jul 2023
Historique:
received:
29
05
2023
revised:
22
06
2023
accepted:
30
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Formulating low-solubility or low-permeability drugs is a challenge, particularly with the low administration volumes required in intranasal drug delivery. Nanoemulsions (NE) can solve both issues, but their production and physical stability can be challenging, particularly when a high proportion of lipids is necessary. Hence, the aim of the present work was to develop a NE with good solubilization capacity for lipophilic drugs like simvastatin and able to promote the absorption of drugs with low permeability like fosphenytoin. Compositions with high proportion of two lipids were screened and characterized. Surprisingly, one of the compositions did not require high energy methods for high droplet size homogeneity. To better understand formulation factors important for this feature, several related compositions were evaluated, and their relative cytotoxicity was screened. Optimized compositions contained a high proportion of propylene glycol monocaprylate NF, formed very homogenous NE using a low-energy phase inversion method, solubilized simvastatin at high drug strength, and promoted a faster intranasal absorption of the hydrophilic prodrug fosphenytoin. Hence, a new highly homogeneous NE obtained by a simple low-energy method was successfully developed, which is a potential alternative for industrial application for the solubilization and protection of lipophilic actives, as well as (co-)administration of hydrophilic molecules.
Identifiants
pubmed: 37514064
pii: pharmaceutics15071878
doi: 10.3390/pharmaceutics15071878
pmc: PMC10384498
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação para a Ciência e Tecnologia
ID : UIDB/00709/2020, UIDP/00709/2020
Organisme : European Commission
ID : CENTRO-01-0145-FEDER-000013 and CENTRO-01-0145-FEDER-181231
Références
Drug Dev Ind Pharm. 2015;41(8):1338-42
pubmed: 25138349
J Control Release. 2018 Jan 28;270:89-100
pubmed: 29199063
J Control Release. 2017 Apr 28;252:28-49
pubmed: 28279798
Biochem Pharmacol. 2023 Aug;214:115644
pubmed: 37321414
Adv Colloid Interface Sci. 2015 Aug;222:581-99
pubmed: 25632889
Eur J Pharm Biopharm. 2023 Jun;187:141-155
pubmed: 37076052
Drug Dev Ind Pharm. 2015;41(12):1922-34
pubmed: 26057769
Eur J Pharm Sci. 2021 Sep 1;164:105918
pubmed: 34174414
Int J Pharm. 2009 Jul 30;377(1-2):142-7
pubmed: 19454306
Pharmaceutics. 2021 Jul 27;13(8):
pubmed: 34452103
Pharmaceutics. 2019 Feb 17;11(2):
pubmed: 30781585
Eur J Pharm Sci. 2020 Jan 1;141:105099
pubmed: 31672614
Pharmaceutics. 2022 Mar 08;14(3):
pubmed: 35335964
Ann N Y Acad Sci. 1961 Jun 17;92:366-71
pubmed: 13748822
J Biomol Struct Dyn. 2017 May;35(7):1529-1546
pubmed: 27484332
Pharmaceutics. 2022 Feb 14;14(2):
pubmed: 35214147
Pharmaceutics. 2022 Sep 26;14(10):
pubmed: 36297487
Pharmaceuticals (Basel). 2022 Mar 28;15(4):
pubmed: 35455409
Int J Pharm. 2019 Jun 30;565:258-268
pubmed: 31095983
Laryngoscope. 2004 Jun;114(6):1037-41
pubmed: 15179209
ACS Biomater Sci Eng. 2021 Jun 14;7(6):2177-2191
pubmed: 33877804
Acta Pharm Sin B. 2021 Apr;11(4):925-940
pubmed: 33996407
J Control Release. 2022 Nov;351:598-622
pubmed: 36183972
J Pharm Biomed Anal. 2000 Aug 15;23(2-3):323-40
pubmed: 10933525
Curr Drug Deliv. 2019;16(10):887-901
pubmed: 31660815
World Neurosurg X. 2023 May 13;19:100211
pubmed: 37251243
Adv Pharm Bull. 2020 Jul;10(3):389-398
pubmed: 32665897
Eur J Pharm Sci. 2006 Nov;29(3-4):278-87
pubmed: 16815001
Int J Pharm. 2021 Jan 5;592:120040
pubmed: 33157214
EBioMedicine. 2023 Apr;90:104484
pubmed: 36907105
Drug Deliv. 2023 Dec;30(1):2174206
pubmed: 36852655
Epilepsy Behav. 2023 Apr;141:109133
pubmed: 36813661